2 Stocks Powering OpenAI's and Anthropic's Revenue Surge in 2026

Anthropic expects roughly $18 billion in revenue this year (more than quadruple last year) and projects about $55 billion next year, fueling strong demand for AI infrastructure. Nvidia supplies the GPUs Anthropic uses and, together with Microsoft, has committed at least $5 billion (possible up to $10 billion) in investment, while Broadcom disclosed roughly $10 billion in custom-chip orders tied to Alphabet plus an additional $11 billion of hardware orders and reported Q4 revenue up ~28% year-over-year to about $18 billion. These developments underscore sizable, near-term revenue and order backlogs for key hardware suppliers and reinforce Anthropic as a major demand driver for cloud and server components ahead of any potential IPO.

Analysis

Market structure: Anthropic's reported ramp implies concentrated demand for ultra-high-end GPUs and datacenter connectivity; winners are NVDA and AVGO plus cloud operators (MSFT, AMZN) that host racks, while smaller GPU rivals and legacy OEMs face pricing pressure and share loss. Expect persistent tight GPU lead-times and >20%+ annual ASP expansion for cutting-edge accelerators through 2026 if Anthropic and peers execute, supporting margin expansion for NVDA/AVGO and continued capex for hyperscalers.

Risk assessment: Key tail risks are (1) AI regulatory/export controls (BIS/US restrictions) that could curb NVDA sales within 30–120 days, (2) Anthropic growth miss or funding shortfall that would unwind backlog, and (3) faster-than-expected ASIC adoption compressing GPU demand over 2–4 years. Short-term (days–weeks) the market will reprice on leaks/earnings; medium-term (3–12 months) depends on order recognition and supply; long-term (2–5 years) is compute-architecture evolution.

Trade implications: Favor concentrated exposure to NVDA and AVGO but size and hedge carefully: NVDA benefits most of compute tightness, AVGO benefits from server interconnect/order backlog. Use pair trades (long NVDA, short AMD) to express share concavity; prefer defined-risk option spreads to capture asymmetric upside while hedging regulatory/event risk around anticipated Anthropic IPO/earnings within 30–90 days.

Contrarian angles: Consensus underestimates concentration risk — a single-customer surge (Anthropic) can create stop-start capex leading to lumpy revenue for suppliers and bargaining power that could force price concessions. History (2016–18 hyperscaler cycles) shows outsized upside but also sharp reversals when orders pause; hedge with tail protection and avoid fully levered directional exposure.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in NVDA over the next 2 weeks, target +25–35% upside over 6–12 months, place a hard stop at -15% (or hedge with a 12-month 25% OTM put allocation of 0.5% of portfolio).
• Establish a 1.5–2% long position in AVGO (benefits from Anthropic backlog) with a 12-month target +15–25% and stop-loss -12%; consider buying a 9–12 month near-the-money LEAP call for 0.75–1% notional if wanting convex upside.
• Execute a relative-value pair: long NVDA 2% / short AMD 1% (or equivalent 3:1 notional) for 3–6 months to capture tech leadership divergence; unwind if NVDA underperforms datacenter rev growth by >5% q/q or if AMD posts >10% GPU market share gains.
• Use options to define risk around catalysts: buy a 3–6 month NVDA call spread (10% OTM long leg) sizing max premium to 0.5–1% portfolio to capture upside to Anthropic/earnings; concurrently allocate 0.25–0.5% to hedge regulatory tail via 9–12 month NVDA/AVGO puts. Monitor BIS export-control announcements and Anthropic S-1/8-K disclosures within the next 30–90 days—if export scope widens to datacenter GPUs, reduce NVDA exposure to <1% immediately.